Pfizer sues J&J over Remicade contracts; drugmakers trim sales forces for rare-disease drugs; Roche's oncology business under siege from biosimilars
Alkermes lobbies lawmakers on its opioid addiction drug; rep salaries rise; SCOTUS rules in favor of Sandoz in biosimilar suit
Teaching hospitals that limit detailing prescribe fewer branded drugs; new ad campaign criticizes drug pricing; Ad Age reports healthcare is fastest growing agency discipline
The drugmaker saw a gap in patient-physician conversation about retinal disease.
Pharma can reach physicians within the EHR, but they must send the right message at the right time, she said at an MM&M event.
Drugmakers can do a better job of organizing dosing information, safety information, and clinical data on their brand websites, a new survey found.
It's becoming less and less likely that an in-person physician/sales rep interaction will take place at the healthcare provider's office.
In the A Thousand Words About NTM campaign, real NTM patients were paired with artists who created original pieces that communicate patients' difficult journey to diagnosis.
To break through and drive a high level of physician interaction, Havas Life Metro and Genentech created an interactive self-guided digital storytelling experience to explain the unique mechanism of action of Gazyva.
Some drugmakers employ unsettling ads; Teva said the FDA may grant quick review for generic EpiPen; Sanofi and Google's Verily partner in diabetes
Valeant terminates Addyi's sales force; the Treasury Department issues new tax-inversion rules; MannKind buys back its marketing rights to Afrezza
A pair of surveys paint a complicated picture of what direction pharma access to healthcare providers is going.
From clinical trials to customer planning, digital can speed the biopharma product launch at each step, said Nancy Phelan, BMS head of commercial operations, at last week's MM&M Leadership Exchange.
Sales reps that focus on creating value for HCPs could find new opportunities and improved access to those physicians, according to Accenture.
The British drugmaker is reviewing the patient-oriented sales model it introduced in 2011.
A study said many sales presentations fail to resonate with payer audiences.
The pharma sales model increasingly relies on key account managers rather than sales reps.
Traditional tactics of connecting with physicians are quickly becoming obsolete.
The SEC said some company drug prices can be made public, 23andMe launched an R&D division, and Public Citizen is asking the FDA to withdraw a proposal it says will undermine drug safety information.
Some IDNs are centralizing decisionmaking at the corporate level and other hospitals are limiting on-site access to sales reps.
Cymbalta and Evista patent losses drove down sales, but Lilly said it does not plan to replenish the sales force it thinned in anticipation of the decline.
The painkiller's marketer will look to partner with another manufacturer to better target primary care physicians, and will also reexamine its sales territories.
Arena's recent quarter shows weight-loss drug Belviq is on the rise. It follows a DTC push and the recent addition of reps by co-marketer Eisai.
Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.
Researchers found that limiting sales rep access and interactions reduces off-label prescriptions for the previously detailed drugs, while also upping off-label prescriptions of the drugs that had not been promoted.
The company unveiled the mix-and-match marketing management tool at the Eye for Pharma conference in Barcelona.
A survey of UK-based general practitioners shows industry websites are not a go-to source for information. Reps did not fare well, either.
Analyst Thomas Wei reviews the prescription slimming category and sees two different realities for Vivus and Arena.
The new network, PD One, will allow reps to connect with HCPs through PDI's Medical Bag.
Lobbying groups say the ad tax draft proposal could wreak havoc throughout the ad industry and its partners, such as publishers and broadcasters, if it were to go through.